Publications by authors named "Morosi C"
Background: Risk-stratification of patients with retroperitoneal sarcomas (RPS) relies on validated nomograms, such as Sarculator. This retrospective study investigated whether radiomic features extracted from computed tomography (CT) imaging could i) enhance the performance of Sarculator and ii) identify G3 dedifferentiated liposarcoma (DDLPS) or leiomyosarcoma (LMS), which are currently consider in a randomized clinical trial testing neoadjuvant chemotherapy.
Methods: Patients with primary localized RPS treated with curative-intent surgery (2011-2015) and available pre-operative CT imaging were included.
Article Synopsis
- The study investigates abdominal venous leiomyosarcoma (AV-LMS), focusing on its origins from veins associated with the sex-hormone drainage pathway (SHDP).
- A retrospective analysis of imaging from 155 patients with confirmed non-uterine abdominal/pelvic LMS revealed that more than half of the tumors originated from venous structures, particularly those linked to the SHDP, including adrenal and ovarian veins.
- Key findings indicate that tumors from the SHDP are prevalent and may lead to a lower risk of distant metastases at diagnosis, with tumor size and SHDP origin being critical factors in predicting metastasis risk.
Article Synopsis
- Pleomorphic liposarcoma (PLPS) is a rare cancer, and this study focused on the surgical outcomes and treatment strategies for patients with non-metastatic PLPS from 2002 to 2019.* -
- The research involved analyzing data from 44 verified cases, finding that 75% of patients survived for at least five years, with larger tumors linked to worse survival outcomes and higher risks of disease-specific death.* -
- The study concluded that aggressive surgery combined with radiation therapy leads to good local control, while smaller Grade 2 tumors might be effectively treated with surgery alone.*
Article Synopsis
- Epithelioid hemangioendothelioma (EHE) is difficult to treat with traditional chemotherapy, prompting researchers to explore new therapies such as sirolimus and identify biomarkers for tumor aggressiveness.
- Scientists created a patient-derived xenograft (PDX) model from an advanced EHE patient to test sirolimus and to study serum levels of Growth/Differentiation Factor 15 (GDF-15) as a potential biomarker.
- The results indicated sirolimus was more effective than doxorubicin in reducing tumor growth and GDF-15 levels, establishing GDF-15 as a promising biomarker for EHE aggressiveness and potentially indicating the effectiveness of sirolimus in patients.
Objective: Evaluate the feasibility and outcomes of the implementation of a routinely prehabilitation nutritional program (PNP) in retroperitoneal sarcoma (RPS) patients.
Summary Background Data: Rate of preoperative malnutrition is scarcely evaluated in RPS patients and the efficacy of a PNP in detecting and reverting malnutrition has not been studied.
Methods: Prospective study in a high-volume reference center for RPS; adult patients with primary or persistent RPS deemed surgically resectable were enrolled in a PNP.
Background: In retroperitoneal leiomyosarcoma (RP LMS), the predominant issue is distant metastasis (DM). We sought to determine variables associated with this outcome and disease-specific death (DSD).
Methods: Data were retrospectively collected on patients with primary RP LMS treated at a high-volume center from 2002 to 2023.
Article Synopsis
- Epithelioid hemangioendothelioma (EHE) is a rare type of cancer with unique features, but its natural history and best treatment practices are not well understood.
- The EURACAN project has created a registry to gather prospective data on newly diagnosed EHE patients to enhance understanding of the disease.
- The study will involve collecting comprehensive patient data from specialized hospitals to identify prognostic factors, treatment efficacy, and to monitor the disease's progression and outcomes over time.
Background: We report on a series of consecutive patients with localized radiation-associated angiosarcoma (RAAS) of the breast region (BR) treated at two Italian sarcoma reference centers.
Materials And Methods: We retrospectively reviewed all cases of primary, localized, resectable RAAS of the BR, treated at one of the two participating institutions from 2000 to 2019. Relapse-free survival (RFS) and overall survival (OS) were calculated.
Article Synopsis
- Congenital mesoblastic nephroma is the most common solid kidney tumor in newborns, and MRI is the preferred method for diagnosis, especially in differentiating it from Wilms tumor.
- This study involved a review of MRI scans from 52 confirmed cases of congenital mesoblastic nephroma, categorizing them into classic, cellular, and mixed types, with a focus on their distinct MRI characteristics.
- Key findings revealed that the classic type was more homogeneous and smaller, while cellular and mixed types were larger and more heterogeneous, with specific MRI signaling patterns noted across all cases.
Angiosarcoma (AS) represents a rare and aggressive vascular sarcoma, posing distinct challenges in clinical management compared to other sarcomas. While the current European Society of Medical Oncology (ESMO) clinical practice guidelines for sarcoma treatment are applicable to AS, its unique aggressiveness and diverse tumor presentations necessitate dedicated and detailed clinical recommendations, which are currently lacking. Notably, considerations regarding surgical extent, radiation therapy (RT), and neoadjuvant/adjuvant chemotherapy vary significantly in localized disease, depending on each different site of onset.
View Article and Find Full Text PDFPurpose: To study plasma levels, efficacy and tolerability of imatinib in a patient affected by metastatic GIST treated with oral Imatinib and undergoing hemodialysis.
Patients And Methods: The patient suffered from metastatic GIST to the liver having a mutation of exon 9 of KIT. He was on hemodialysis and received first-line treatment with imatinib 400 mg/day.
Article Synopsis
- Pediatric non-rhabdomyosarcoma soft-tissue sarcomas (NRSTS) are tough tumors that don’t have the best treatment options for some patients, especially if they can’t be surgically removed at first.
- A study looked at 71 patients under 21 who were treated for NRSTS from 1990 to 2021, finding that many had large, dangerous tumors and most received chemotherapy before surgery.
- Results showed that while the survival rates were not great, patients who responded well to chemotherapy and had successful surgeries had a better chance of living longer, highlighting the need for better treatment plans.
Purpose: A randomized trial was conducted to compare neoadjuvant standard (S) anthracycline + ifosfamide (AI) regimen with histology-tailored (HT) regimen in selected localized high-risk soft tissue sarcoma (STS). The results of the trial demonstrated the superiority of S in all STS histologies except for high-grade myxoid liposarcoma (HG-MLPS) where S and HT appeared to be equivalent. To further evaluate the noninferiority of HT compared with S, the HG-MLPS cohort was expanded.
View Article and Find Full Text PDFBackground: To investigate the activity of regorafenib in advanced solitary fibrous tumour (SFT).
Methods: An Italian monocentric investigator-initiated exploratory single-arm Phase II trial was conducted of regorafenib in adult patients with advanced and progressive SFT, until progression or limiting toxicity. Prior treatment with antiangiogenics was allowed.
Background: The aim of this study was to assess the clinical impact of indeterminate pulmonary nodules (no more than four pulmonary nodules of less than 5 mm or one nodule measuring between 5 and less than 10 mm by computed tomography [CT]) in children and adolescents with adult-type non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) at diagnosis.
Methods: Patients with NRSTS treated in 11 centers as part of the European paediatric Soft Tissue Sarcoma Study Group (EpSSG) were retrospectively assessed. Local radiologists, blinded to clinical information except for patients' age and tumor histotype, reviewed the chest CT at diagnosis and filled out a case report form.
Objective: To investigate the feasibility of diffusion-weighted magnetic resonance imaging (DW-MRI) as a predictive imaging marker after neoadjuvant chemotherapy in patients with rhabdomyosarcoma.
Material And Methods: We performed a multicenter retrospective study including pediatric, adolescent and young adult patients with rhabdomyosarcoma, Intergroup Rhabdomyosarcoma Study group III/IV, treated according to the European paediatric Soft tissue sarcoma Study Group (EpSSG) RMS2005 or MTS2008 studies. DW-MRI was performed according to institutional protocols.
Rhabdomyosarcoma is the most common soft-tissue neoplasm in the pediatric population. The survival of children with rhabdomyosarcoma has only marginally improved over the past 25 years and remains poor for those with metastatic disease. A significant challenge to advances in treatment of rhabdomyosarcoma is the relative rarity of this disease, necessitating years to complete clinical trials.
View Article and Find Full Text PDFBackground: Refractory or metastatic nasopharyngeal carcinoma (NPC) patients have a poor prognosis due to the lack of effective salvage treatments and prolonged survival by means of combination chemotherapy being described only for a minority of younger patients with oligometastatic disease. Targeting the Epstein - Barr virus (EBV) proteins expressed in NPC cells has been shown to be a feasible strategy that could help control systemic disease.
Patients And Methods: Between 2011 and 2014, 16 patients with recurrent/metastatic EBV-NPC received first-line chemotherapy (CT) followed by 2 doses of autologous cytotoxic EBV specific T-lymphocytes (15-25 x 10 total cells/dose, 2 weeks apart), based on our previous studies showing the feasibility and efficacy of this infusion regimen.
Background: Surgery is the treatment mainstay in retroperitoneal sarcoma (RPS), a frontline comprehensive approach based on tumor removal en bloc with adherent viscera is mandatory especially for liposarcoma, where the normal retroperitoneal fat is undistinguishable from the well-differentiated tumor component. In this video, a reproducible and standardized six-stage approach to a primary right retroperitoneal liposarcoma is presented.
Patient And Methods: A 23-cm right retroperitoneal, well-differentiated liposarcoma was diagnosed in a 68-year-old female patient in December 2021.
Importance: Preclinical data about the synergistic activity of radiotherapy (RT) and trabectedin have been reported. The combination of trabectedin and RT in treating myxoid liposarcomas appears worth exploring.
Objective: To explore the effectiveness and safety of trabectedin combined with RT.
Each year approximately 35,000 children and adolescents are diagnosed with cancer in Europe. Five-year survival rates have improved and now reach 80% in most European countries, thanks to a combination of chemotherapy, radiotherapy, and surgery. To date, there are more than 44,000 Italians still living several years after being diagnosed with cancer in developmental age.
View Article and Find Full Text PDFObjective: To report on a retrospective study of primary DSRCT aiming at characterizing long-term survivors (LTS).
Methods: All consecutive patients treated at our institution for a primary DSRCT between 2000 and 2021 were retrospectively identified. Patients received multiagent chemotherapy ± surgery ± hyperthermic intraperitoneal chemotherapy (HIPEC) ± whole abdomino-pelvic radiotherapy (WAP-RT) ± high-dose chemotherapy ± maintenance chemotherapy (MC).
Beckwith-Wiedemann Syndrome (BWS) is a pediatric overgrowth disorder involving a predisposition to embryonal tumors. Most of the tumors associated with BWS occur in the first 8-10 years of life, and the most common is Wilms tumor (WT). BWS clinical heterogeneity includes subtle overgrowth features or even silent phenotypes, and WT may be the presenting symptom of BWS.
View Article and Find Full Text PDFArticle Synopsis
- Tenosynovial giant cell tumour (TGCT) is a rare tumor that grows around joints and tendons, with two types: nodular (less aggressive) and diffuse (more aggressive).
- TGCT can lead to chronic pain and negatively affect a person's quality of life, though it's not usually life-threatening.
- A global meeting in June 2022 brought together experts and patients to establish better treatment guidelines for TGCT, given the challenges in making consistent treatment choices worldwide.